Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Travere Therapeutics, Inc. - Common Stock (NQ:TVTX)

14.20 -0.97 (-6.43%)
Streaming Delayed Price Updated: 3:11 PM EDT, Apr 8, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Travere Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Where Travere Therapeutics Stands With Analysts
Via Benzinga
Travere Therapeutics Initiates Pivotal Phase 3 Clinical Trial of Pegtibatinase for the Treatment of Classical Homocystinuria (HCU)
Potential for pegtibatinase to become first disease-modifying treatment for classical HCU; topline data expected in 2026 
From Travere Therapeutics, Inc.
Via GlobeNewswire
THOR Industries Reports Upbeat Earnings, Joins Dave & Buster's Entertainment, Campbell Soup And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher, with the Dow Jones index gaining more than 50 points on Wednesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
What's Going On With Travere Therapeutics Stock?
Travere Therapeutics, Inc. (NASDAQ: TVTX) shares are trading higher Tuesday. 
Via Benzinga
Travere Therapeutics Inc. (NASDAQ: TVTX) Near the Top of Equities by Percentage Gain on 12/5
Via Investor Brand Network
Where Travere Therapeutics Stands With Analysts
Via Benzinga
Crude Oil Moves Lower; AutoZone Profit Tops Views
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite trading higher on Tuesday. The Dow traded down 0.18% to 36,138.19 while the NASDAQ rose 0.19% to 14,212.19. The S&P 500... 
Via Benzinga
Topics Stocks
Exposures Fossil Fuels US Equities
Why Daktronics Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Shares of Daktronics, Inc. (NASDAQ: DAKT) moved lower during Tuesday’s session following weak quarterly results. 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Intraday Session
Via Benzinga
Preview: Travere Therapeutics's Earnings
Via Benzinga
Expert Ratings for Travere Therapeutics
Via Benzinga
NIO Reports Q3 Results, Joins Hovnanian Enterprises, Signet Jewelers And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded mostly lower, with the Dow Jones index falling more than 100 points on Tuesday. 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Monday's After-Market Session
Via Benzinga
Travere Completes Successful pre-NDA Meeting for FILSPARI in IgAN; Provides Regulatory Updates for both IgAN and FSGS
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Present at the 6th Annual Evercore ISI HealthCONx Conference
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Third Quarter 2023 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Announces Late-Breaking Data from Phase 3 Studies of Sparsentan in IgAN and FSGS Published in The Lancet and The NEJM Respectively and Presented at the American Society of Nephrology (ASN) Kidney Week 2023
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics to Report Third Quarter 2023 Financial Results
From Travere Therapeutics, Inc.
Via GlobeNewswire
Earnings Scheduled For November 7, 2023
Companies Reporting Before The Bell • CorEnergy Infr Tr (NYSE:CORR) is estimated to report earnings for its third quarter. 
Via Benzinga
Travere Therapeutics to Present Abstracts at the American Society of Nephrology (ASN) Kidney Week 2023
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shareholder Notice: Investigation over Possible Breaches of Fiduciary Duties
San Diego, CA -- (SBWIRE) -- 09/29/2023 -- An investigation was announced over potential breaches of fiduciary duties by certain directors at Travere Therapeutics, Inc. 
Via SBWire
Travere Therapeutics to Present Abstracts at the 17th International Symposium on IgA Nephropathy (IIGANN 2023)
From Travere Therapeutics, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2023
Via Benzinga
Micron Technology To Rally Around 21%? Here Are 10 Other Analyst Forecasts For Friday
Loop Capital increased the price target for Splunk Inc. (NASDAQ: SPLK) from $135 to $157. Loop Capital analyst Yun Kim downgraded the stock from Buy to Hold. Splunk shares fell 0.1% to $144.25 in... 
Via Benzinga
Back To Back Trial Failures: Analyst Weighs In On Travere Therapeutics' Prospects, Challenges
William Blair downgraded Travere Therapeutics Inc (NASDAQ: TVTX)  
Via Benzinga
Dow Tumbles 200 Points; Darden Restaurants Posts Upbeat Profit
U.S. stocks traded lower toward the end of trading, with the Dow Jones falling around 200 points on Thursday. The Dow traded down 0.58% to 34,239.48 while the NASDAQ fell 1.20% to 13,307.77. The S&P... 
Via Benzinga
Topics Stocks
Exposures US Equities
12 Health Care Stocks Moving In Thursday's Intraday Session
Via Benzinga
Why Seelos Therapeutics Shares Are Trading Lower By 31%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Gainers MSP Recovery, Inc. (NASDAQ: LIFW) shares climbed 81.5% to $0.2793 after jumping 64% on Wednesday. 
Via Benzinga
Why Shares of Travere Therapeutics Are Slumping Thursday
A mixed trial could hurt a kidney drug's chances of full approval. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.